期刊文献+

药物洗脱支架内再狭窄再次置人支架的远期疗效和安全性 被引量:5

Long-term safety and efficacy of re-implementation of drug eluting stent in implantation restenosis patients
下载PDF
导出
摘要 目的探讨对药物洗脱支架(DES)置入后发生再狭窄(ISR)患者再次实施DES置入术的远期疗效和安全性。方法选择植入DES的冠心病患者,经冠状动脉造影检查证实发生再狭窄(ISR≥50%),并且再次置入DES治疗ISR介入手术成功的患者。985例DES-ISR患者根据狭窄类型分为局限性狭窄组130例(13.2%),弥漫性狭窄组699例(71.0%),闭塞性狭窄组156例(15.8%)。随访观察3组患者的远期(6个月、12个月)疗效及安全性。结果经过6个月的随访,局限性狭窄组患者主要不良心血管事件(MACE)的发生率为3.85%(5/130);弥漫性狭窄组患者MACE的发生率为2.72%(19/699);闭塞狭窄组患者MACE的发生率为3.21%(5/156),3组6个月的随访结果差异无统计学意义(P>0.05)。经过12个月的随访,局限性狭窄组患者MACE的发生率为13.08%(17/130);弥漫性狭窄组患者MACE的发生率为9.16%(64/699);闭塞狭窄组患者MACE的发生率为9.62%(15/156),3组12个月的随访结果差异亦无统计学意义(P>0.05)。结论目前对于DES-ISR患者来说,不论ISR的类型,再次置入DES都是一种有效的方法。 Objective To observe the long-term safety and efficacy of drug eluting stent (DES) implantation restenosis (ISR) patients're-implementation of DES implantation. Methods Selected DES implantation in patients with coronary heart disease, coronary angiography examination confirmed the occurrence of restenosis ( ISR ≥ 50% ), and once again in the DES intervention ISR operation successful patients. 985 cases of DES ISR patients according to narrow type were divided into localized stenosis group with 130 cases (13.2%), diffuse stenosis group with 699 cases (71.0%), occlusive stenosis group with 156 cases ( 15.8% ). Long ternl follow-up observation of efficacy and safety in the 3 groups (6 months, 12 months). Results After 6 months of follow-up, localized stenosis group with major adverse cardiovascular events (MACE) occurred in 3.85% (5/130) ; in diffuse stenosis group, the incidence of MACE was 2.72% (19/699) ; in occlusion stenosis group, the incidence of MACE was 3.21% (5/156), no statistically significant of 6 month follow-up were found among 3 groups ( P 〉 0.05). After 12 months of follow-up, localized stenosis groupsqneidenee of MACE was 13.08% (17/130) ; in diffuse steno- sis group, the incidence of MACE was 9.16% (64/699) ; in occlusion stenosis group, the incidence of MACE was 9.62% (15/156) , the follow-up results of 3 groups of 12 months had no statistical difference significance ( P 〉 0.05 ). Conclusion It demonstrated that the re-implementation DES implantation was an effective alternative for treatment of DES ISR.
出处 《疑难病杂志》 CAS 2014年第6期555-557,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 药物洗脱支架 支架内再狭窄 支架再次置入 远期疗效 安全性 Drug eluting stents In-stent restenosis Repeat drug eluting stents implantation Long term efficacy Safety
  • 相关文献

参考文献13

  • 1Colombo A, Latib A. Treatment of drug-eluting stent restenosis with an- other drug-eluting stent:do not fail the second time[J]. Revista Espan- ola de Cardiologia, 2008, 61 ( 11 ) : 1120-1122.
  • 2Byrne RA, Neumann FJ, Mehilli JA, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with rest- enosis after implantation of a drug-eluting stent ( ISAR-DESIRE 3 ) : a randomised, open-label trial [ J ]. Lancet, 2013, 381 (9865) : 461- 467.
  • 3Dangas GD, Claessen BE, Caixeta AA, et al. In-stent restenosis in the Drug-Eluting stent era[ J]. Journal of the American College of Cardiolo- gy, 2010, 56(23) : 1897-1907.
  • 4Mehran R, Dangas G, Abixaid AS, et al. Angiographic patterns of in- stent restenosis: classification and implications for long-term out-come [ J]. Circulation, 1999, 100 (18) : 1872-1878.
  • 5Jukema JW, Versehuren JJ, Ahmed TA, et al. Restenosis after PCI. Partl: patho-physiology and riskfactors [ J ]. Nat Rev, 2011, 132 ( 9 ) : 1-10.
  • 6史长生,王珏,司一民,杨长春.中药防治经皮腔内血管成形术后再狭窄的研究进展[J].临床误诊误治,2009,22(4):11-12. 被引量:4
  • 7毛利荣,马涛,张瑞峰,张立欣,房体静,文军,高海明.冠状动脉支架置入围术期应用前列地尔对C反应蛋白及支架内再狭窄的影响[J].疑难病杂志,2012,11(5):372-374. 被引量:6
  • 8孙涛,李志忠,张京梅,王苏,陶英,阴赪茜,赵战勇,阙斌,张铭,陈顺华.睡眠呼吸暂停综合征同冠状动脉支架术后再狭窄之间关系初步研究[J].中国医药,2009,4(5):350-352. 被引量:6
  • 9Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 ( Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2 ) study [ J ]. Journal of the American College of Cardiology, 2010, 55 (24) : 2710-2716.
  • 10Byrne RA, Neumann FJ, Mehilli JA, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with rest- enosis after implantation of a drug-eluting stent ( ISAR-DESIRE 3 ) : a randomised, open-label trial [ J ]. Lancet, 2013, 381 ( 9865 ) : 461- 467.

二级参考文献30

共引文献13

同被引文献81

  • 1李博,朱平先,吴清华.64排128层螺旋CT在冠状动脉与支架术后狭窄诊断中的应用价值[J].中华临床医师杂志(电子版),2012,6(20):167-169. 被引量:25
  • 2杨娜,赵学忠,王全伟,田晓庆,郝守艳.冠状动脉支架内再狭窄的研究进展[J].中国老年学杂志,2014,34(6):1731-1733. 被引量:14
  • 3Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis[J].Lancet, 2007,370(9591):937-948.
  • 4ColomboA, LatibA. Treatment of drug eluting stent restenosis with another drug-eluting stent: do not fail the second time [J].Rev Esp Cardiol, 2008,61(11):1120-1122.
  • 5Bashore TM, Bate ER, Berger PB, et al. American College of Cardiology/Society for Cardiac Angiography and Interventions clinical expert consensus on cardiac catheterization laboratory standards[J].Jam Cardiol, 2007,37(8):2170-2214.
  • 6LeschkaS, Alkadhi H, PlassA, et aT. Accuracy of MSCT coronary angiography with 64-slice technology: first experience[J]. Eur Heart J, 2011,26(15):1482-1487.
  • 7He M, Gong Y, Shi J, Pan Z, Zou H, et al. Plasma MicroRNhs as Potential Noninvasive Biomarkers for In-Stent Restenosis [J].PLoS ONE, 2014,9(11):e112043.
  • 8Kang SJ, Ming GS, Park DW, et al.Mechanisms of in-stent restenosisafter drug-eluting stent implantation: intravascular ultrasound analysis[J].Circ Cardiovasc Interv, 2011,4(1): 9-14.
  • 9Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting[J].Rev Endocr Metab Disord, 2010,11(1):75-86.
  • 10Spadaccio C, Patti G, De Marco F, Pollari F, et al. Usefulness of preprocedural levels of advanced glycation end products topredict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris(from the Prospective ARMYDA-AGEs Study) [J].Am J Cardiol, 2013.112(1):21-26.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部